Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Jun 2019

Genetic testing and PARP inhibitors in metastatic prostate cancer

Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019

Breast cancer highlights from ASCO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )
6 Jun 2019

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

Dr Zahi Mitri - OHSU Hospital, Portland, USA
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )
6 Jun 2019

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
6 Jun 2019

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )
6 Jun 2019

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019

Potential of PARP inhibitors for metastatic breast cancer

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019